1
Tarran Jones
Chesnut Robert W, Polley Margaret J, Paulson James C, Jones S Tarran, Saldanha Jose W, Bendig Mary M, Kriegler Michael, Perez Carl, Bayer Robert, Nunn Michael: Antibodies to p-selectin and their uses. Cytel, November 5, 1997: EP0804235-A1

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...


2
Bendig Mary M, Kettleborough Catherine A, Saldanha Jose: Humanized and chimeric monoclonal antibodies.. Merck Patent, March 17, 1993: EP0531472-A1 (4 worldwide citation)

The invention relates to new humanized monoclonal antibodies deriving from murine anti-EGFR antibody 425 comprising an artificial modified consensus sequence at least of the FRs in the variable region of the heavy chain of human immunoglobulins. The invention relates, furthermore, to humanized and c ...


3
Tarran Jones
Bendig Mary M, Leger Olivier J, Saldanha Jose, Jones S Tarran, Yednock Ted A: Therapeutic uses of humanized antibodies against alpha-4 integrin. Athena Neurosciences, June 16, 1999: EP0921815-A1

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


4
Tarran Jones
Ponath Paul D, Ringler Douglas J, Jones S Tarran, Newman Walter, Saldanha Jose, Bendig Mary M: Humanized immunoglobulin reactive with alpha4beta7 integrin. Millennium Pharm, October 11, 2006: EP1710314-A1

The present invention relates to humanized immunoglobulins having binding specificity for +-47 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In on ...


5
Tarran Jones
Bendig Mary M, Leger Olivier J, Saldanha Jose, Jones Tarran S, Yednock Theodore A: Humanized antibodies against leukocyte adhesion molecule vla-4. Elan Pharm, March 7, 2007: EP1759709-A1

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for the treatment of multiple sclerosis.


6
Tarran Jones
Bendig Mary M, Leger Olivier J, Saldanha Jose, Jones Tarran S: Humanized antibodies against leukocyte adhesion molecule vla-4. Athena Neurosciences, November 5, 1997: EP0804237-A1

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.


7
Bendig Mary M, Kettleborough Catherine A, Saldanha Jose: Anticorps monoclonaux humanises et chimeriques, Humanised and chimeric monoclonal antibodies. Merck Patent Gesellschaft Mit Beschraenkter Haftung, Merck Patent Gesellschaft Mit Beschraenkter Haftung, FETHERSTONHAUGH & CO, September 7, 1992: CA2082160

The invention relates to new humanized monoclonal antibody comprising an artificial modified consensus sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The invention relates, furthermore, to corre-sponding humanized and chimeric monoclonal antibodies which a ...


8
Kettleborough Catherine A, Bendig Mary M, Ansell Keith H, Gussow Detlef, Adan Jaime, Mitjans Francesc, Rosell Elisabet, Blasco Francesc, Piulats Jaime: Fragments danticorps a simple chaine anti-fvs et anticorps anti-egfr, Anti-egfr single-chain fvs and anti-egfr antibodies. Merck Patent Gesellschaft Mit Beschraenkter Haftung, Fetherstonhaugh & Co, December 8, 2009: CA2163012

This invention relates to new anti-EGFR antibodies and single-chain Fvs (scFvs) thereof which can be obtained from phage-antibodylibraries constructed from cells of an immunized mammalian, preferably a mouse. Two of the single-chain Fvs isolated from the phage-antibody libraries were engineered to c ...


9
Kettleborough A Cathrine, Bendig Mary M, Ansell Keith H, Güssow Detlef, Adan Jaime, Mitjans Francesc, Rosell Elisabet, Blasco Francesc, Piulats Jaime: Anti-egfr single-chain fvs and anti-egfr antibodies. Merck Patent, Kettleborough A Cathrine, Bendig Mary M, Ansell Keith H, Güssow Detlef, Adan Jaime, Mitjans Francesc, Rosell Elisabet, Blasco Francesc, Piulats Jaime, MERCK PATENT, September 21, 1995: WO/1995/025167

This invention relates to new anti-EGFR antibodies and single-chain Fvs (scFvs) thereof which can be obtained from phage-antibody libraries constructed from cells of an immunized mammalian, preferably a mouse. Two of the single-chain Fvs isolated from the phage-antibody libraries were engineered to ...


10
Bendig Mary M, Jones Tim D, Longstaff Marian, Hellendoorn Koen: Chimaeric plant viruses with mucin peptides. The Dow Chemical Company, Bendig Mary M, Jones Tim D, Longstaff Marian, Hellendoorn Koen, KIMBLE Karen L, March 15, 2001: WO/2001/018199

Mucin peptide epitopes are inserted into the coat protein of a plant virus (e.g. a comovirus such as CPMV) having a beta-barrel structure at an immunogenically effective site, such as in a loop connecting beta sheets or at/near the C-terminus. The resulting chimaeric virus particles are extremely im ...